Catalyst Wire Dossier Catalyst Wire Dossier

Dulanermin (rhApo2L)

dulanermin · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dulanermin (rhApo2L), covering 2016-11-02 to 2016-11-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer [Phase 1]

See pricing